Home・Stock List・Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Closed

SectorHealthcare

162.78 2.19

Buy Sell

Overview

Share price change

24h

Current

Min

158.96

Max

164.5

Key metrics
By Trading Economics
Income	-54M 144M
Sales	145M 959M
P/E Sector Avg	24.303 68.51
EPS	2.36
Profit margin	15.057
Employees	2,500
EBITDA	-64M 190M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.2% upside

Dividends
By Acuity
Next Earnings	27 Oct 2026

Market Stats
By TradingEconomics
Market Cap	-1B 17B
Previous open	160.59
Previous close	162.78

News Sentiment

By Acuity

50%

151 / 340 Healthcare

Neurocrine Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2026, 19:46 UTC

News

Event

Social Media

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist for obesity, boosting shares during Friday's session.

6 Aug 2026, 19:36 UTC

Neurocrine Biosciences Inc shares are lower during Thursday's session, continuing a decline since Wednesday's close, with no specific news identified.

5 Aug 2026, 23:46 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, buoyed by investor interest despite disappointing private sector employment data.

4 Aug 2026, 19:26 UTC

News

Wedbush raised its price target on Neurocrine Biosciences to $194, while Canaccord Genuity increased its target to $210. Shares are trading roughly flat.

3 Aug 2026, 20:51 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid broader market gains.

31 Jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

30 Jul 2026, 21:51 UTC

News

Neurocrine Biosciences reported second-quarter revenues of $959 million and raised 2026 INGREZZA sales guidance, with shares trading higher in after-market hours.

29 Jul 2026, 18:46 UTC

Neurocrine Biosciences Inc shares are trading lower today with no specific news identified. The stock fluctuated earlier in the session amid broader market activity.

28 Jul 2026, 23:41 UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, rebounding from an earlier dip and maintaining a position above the 20-day moving average.

27 Jul 2026, 19:21 UTC

Social Media

Neurocrine Biosciences shares are higher as Cantor Schimmer ranks it among top picks, citing undervaluation and expected advancements in its portfolio.

24 Jul 2026, 20:07 UTC

Neurocrine Biosciences Inc shares are higher today, despite an earlier pullback. Broader market sentiment is influenced by falling oil prices easing inflation concerns.

22 Jul 2026, 19:51 UTC

News

Neurocrine Biosciences Inc. appointed Samir Siddhanti as Chief Business Officer. Despite this leadership change, shares are trading lower amid cautious investor sentiment.

21 Jul 2026, 19:51 UTC

News

Neurocrine shares rise after Guggenheim raises price target to $200.

20 Jul 2026, 23:46 UTC

Neurocrine Biosciences Inc is trading higher in after-market hours, maintaining a strong performance above its 20-day moving average and near its one-month range.

Peer Comparison

Price change

Neurocrine Biosciences Inc Forecast

Price Target

By TipRanks

32.2% upside

12 Months Forecast

Average 211.28 USD 32.2%

High 249 USD

Low 170 USD

Based on 26 Wall Street analysts offering 12 month price targets forNeurocrine Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

26 ratings

Buy

Hold

Sell

Based on 26 analysts giving stock ratings to Neurocrine Biosciences Inc - Dist in the past 3 months.

Sentiment

By Acuity

151 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.